Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Summit Medical Group

Neither a doctor nor a teaching hospital

Research payments

$4,742,976

798 payments

Through program year 2025, Summit Medical Group is reported as receiving $4,742,976 in research payments, across 798 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $542,551 19
2024 Research $829,379 135
2023 Research $271,783 99
2022 Research $1,132,903 106
2021 Research $264,762 79
2020 Research $1,153,461 205
2019 Research $548,137 155

Breakdown

Who paid Research payments · program years 2019–2025
  1. BeiGene, Ltd. $2,211,712 111 payments
  2. Seattle Genetics, Inc. $478,667 59 payments
  3. BeOne Medicines Ltd. $349,180 7 payments
  4. Pfizer Inc. $294,979 47 payments
  5. Incyte Corporation $246,412 285 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $216,084 141 payments
  7. Eli Lilly and Company $183,855 12 payments
  8. E.R. Squibb & Sons, L.L.C. $164,613 12 payments
  9. Acerta Pharma LLC $152,341 15 payments
  10. AstraZeneca Pharmaceuticals LP $84,933 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib $1,087,447 45 payments
  2. A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $510,589 26 payments
  3. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib $493,920 9 payments
  4. An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies $399,388 23 payments
  5. An Openlabel Multicenter Randomized Phase 3 Study of Firstline Encorafenib Plus Cetuximab With Or Without Chemotherapy Versus Standard of Care Therapy With A Safety Leadin of Encorafenib and Cetuximab Plus Chemotherapy in Participants With Metastatic Braf V600emutant Colorectal Cancer $243,282 41 payments
  6. Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-negative breast cancer $213,681 41 payments
  7. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $170,640 7 payments
  8. A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $149,647 7 payments
  9. BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC $117,146 86 payments
  10. Phase III Study - Breast Cancer HR Pos HER2 Neg Neo adjuvant $110,185 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record